A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus

November 14, 2022 updated by: Prasad G. Iyer, Mayo Clinic

Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma by a Sponge on String Device

This study is being done to collect data on the potential use of a sponge on a string device as a non-invasive tool in evaluating patients with Barrett's Esophagus compared to healthy controls.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study will be conducted in two phases: Phase 1 and Phase 2. Phase 1 will consist of determining the most optimal sponge on a string design (25 mm sponge 20 pores/inch or 25 mm sponge 10 pores/inch) chosen based on participant acceptance, tolerability, mucosal irritation and DNA yield, using a randomized factorial design pilot trial. Participants will first undergo the sponge on a string test followed by clinical endoscopy. Following completion of Phase 1 trial, the most optimal sponge on a string configuration will be chosen for Phase 2. Phase 2 will be conducted using a single size sponge with the same porosity configuration selected from Phase 1. Study procedures, testing and follow up will be the same as Phase 1.

Study Type

Interventional

Enrollment (Actual)

242

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Scottsdale, Arizona, United States, 85259
        • Mayo Clinic
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Mayo Clinic
    • Minnesota
      • Mankato, Minnesota, United States, 56001
        • Mayo Clinic Health System - Mankato
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic in Rochester
    • New York
      • Manhasset, New York, United States, 11030
        • Northwell Health
    • Texas
      • Dallas, Texas, United States, 75246
        • Baylor University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Subjects with known Barrett's Esophagus (BE).

  • Patients with a BE segment ≥ 1cm in maximal extent endoscopically.
  • Histology showing evidence of intestinal metaplasia with or without presence of dysplasia.
  • Undergoing clinically indicated endoscopy. Subjects without known evidence of BE - Undergoing clinically indicated diagnostic endoscopy

Exclusion Criteria:

  • Subjects with known BE.

    • Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with history of endoscopic mucosal resection alone will not be excluded.
    • Patients with history of esophageal resection for esophageal carcinoma. Subjects with or without known evidence of BE (on history or review of medical records).
    • Pregnant or lactating females.
    • Patients who are unable to consent.
    • Patients with current history of eosinophilic esophagitis, achalasia or uninvestigated dysphagia.
    • Patients on oral anticoagulation including Coumadin, Warfarin.
    • Patients on antiplatelet agents including Clopidogrel, unless discontinued for 3 days prior to the sponge procedure.
    • Patients on oral thrombin inhibitors including Dabigatran and oral factor X a inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for 3 days prior to the sponge procedure.
    • Patients with history of known varices or cirrhosis.
    • Patients with history of esophageal resection for esophageal carcinoma.
    • Patients with congenital or acquired bleeding diatheses.
    • Patients with a history of esophageal squamous dysplasia.
    • Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SCREENING
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Phase 1: Sponge on a String 25 mm 10 pores/inch
In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
Procedure: Biopsy
Undergo biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Procedure: Biospecimen Collection
Undergo collection of blood sample
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
Procedure: Endoscopic Procedure
Undergo endoscopy
Other Names:
  • Endoscopy
  • Endoscopic Examination
Device: Swallowable Sponge Cell Sampling Device
Undergo swallowable sponge cell sampling assessment
Other Names:
  • Swallowable Sponge
  • Swallowable Sponge Device
  • Cytosponge
EXPERIMENTAL: Phase 1: Sponge on a String 25 mm 20 pores/inch
In phase 1 of the study, subjects will be assigned to swallow a capsule sponge device 25 mm 20 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
Procedure: Biopsy
Undergo biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Procedure: Biospecimen Collection
Undergo collection of blood sample
Other Names:
  • Biological Sample Collection
  • Biospecimen Collected
  • Specimen Collection
Procedure: Endoscopic Procedure
Undergo endoscopy
Other Names:
  • Endoscopy
  • Endoscopic Examination
Device: Swallowable Sponge Cell Sampling Device
Undergo swallowable sponge cell sampling assessment
Other Names:
  • Swallowable Sponge
  • Swallowable Sponge Device
  • Cytosponge
EXPERIMENTAL: Phase 2: Cases - Barrett's Esophagus
In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
Procedure: Biopsy
Undergo biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Procedure: Endoscopic Procedure
Undergo endoscopy
Other Names:
  • Endoscopy
  • Endoscopic Examination
Device: Swallowable Sponge Cell Sampling Device
Undergo swallowable sponge cell sampling assessment
Other Names:
  • Swallowable Sponge
  • Swallowable Sponge Device
  • Cytosponge
EXPERIMENTAL: Phase 2: Controls - No Barrett's Esophagus
In phase 2 of the study, additional subjects will be assigned to swallow a capsule sponge device 25 mm 10 pores/inch to collect cells and cellular material from the mucosa in the esophagus prior to scheduled for a clinically indicated upper endoscopy
Procedure: Biopsy
Undergo biopsy
Other Names:
  • Bx
  • BIOPSY_TYPE
Procedure: Endoscopic Procedure
Undergo endoscopy
Other Names:
  • Endoscopy
  • Endoscopic Examination
Device: Swallowable Sponge Cell Sampling Device
Undergo swallowable sponge cell sampling assessment
Other Names:
  • Swallowable Sponge
  • Swallowable Sponge Device
  • Cytosponge

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Subjects That Would Have This Procedure Again
Time Frame: Within 24 hours of the capsule sponge administration
Number of subjects that answered yes to the self-reported question "Would you choose to have this procedure again to screen for Barrett's esophagus?"
Within 24 hours of the capsule sponge administration
Tolerability of Swallowing the Sponge Device
Time Frame: Within 24 hours of the capsule sponge administration
Measured using a self-reported 5-item tolerability assessment rating discomfort during the procedure on a Likert scale of 0-10; 10 representing the "worst experience" and 0 the "best experience." This scale allows a comprehensive and individual assessment of the degree of pain, choking, gagging, anxiety and overall experienced during the procedure.
Within 24 hours of the capsule sponge administration
Mucosal Irritation
Time Frame: Within 24 hours of the capsule sponge administration
Measured using a mucosal injury score (ranging from 1=no trauma to 5=severe) was scored from video recordings of the subsequent endoscopy conducted
Within 24 hours of the capsule sponge administration
DNA Yield
Time Frame: Within 24 hours of the capsule sponge administration
Total amount of DNA obtained from esophageal cytology specimens collected by the capsule sponge devices.
Within 24 hours of the capsule sponge administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sensitivity of Barrett's Dysplasia Detection
Time Frame: Within 24 hours of the capsule sponge administration
The sensitivity methylated DNA markers detected by the capsule sponge, in making a diagnosis of BE related dysplasia will be assessed using endoscopic surveillance biopsy histology as a gold standard.
Within 24 hours of the capsule sponge administration
Specificity of Barrett's Dysplasia Detection
Time Frame: Within 24 hours of the capsule sponge administration
The specificity of methylated DNA markers detected by the capsule sponge, in identifying subjects without a diagnosis of BE related dysplasia will be assessed using endoscopic surveillance biopsy histology as a gold standard.
Within 24 hours of the capsule sponge administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Collaborators

National Cancer Institute (NCI)
Exact Sciences Corporation

Investigators

  • Principal Investigator: Prasad G Iyer, M.D., Mayo Clinic in Rochester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 15, 2015

Primary Completion (ACTUAL)

June 29, 2021

Study Completion (ACTUAL)

July 8, 2021

Study Registration Dates

First Submitted

September 21, 2015

First Submitted That Met QC Criteria

September 24, 2015

First Posted (ESTIMATE)

September 25, 2015

Study Record Updates

Last Update Posted (ACTUAL)

November 17, 2022

Last Update Submitted That Met QC Criteria

November 14, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 15-004540 (OTHER: Mayo Clinic in Rochester)
  • P30CA015083 (U.S. NIH Grant/Contract)
  • NCI-2022-08390 (REGISTRY: CTRP (Clinical Trial Reporting Program))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Barrett Esophagus

Clinical Trials on Biopsy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe